RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers

Metastatic Cancers Clinical Trial

Official title:
RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers

Status Completed

Clinical Trial Summary

Phase I clinical trial of hypofractionated radiotherapy to an isolated index lesion in combination with the PD-1 inhibitor, Pembrolizumab in patients with metastatic cancers who have failed anti-PD-1 therapy (melanoma and NSCLC) and patients with metastatic cancers who have have progressed after at least one regimen of systemic therapy (breast, pancreas, and other).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02303990
Study type	Interventional
Source	Abramson Cancer Center of the University of Pennsylvania
Contact
Status	Completed
Phase	Phase 1
Start date	January 8, 2015
Completion date	December 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT01723306` - Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas	Phase 2
Active, not recruiting	`NCT02304809` - Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations	Phase 2
Completed	`NCT02663232` - Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma
Recruiting	`NCT02155621` - Personalized Oncogenomics (POG) Program of British Columbia	N/A
Recruiting	`NCT06085716` - Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers	Phase 2/Phase 3
Completed	`NCT02701907` - EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies	N/A
Terminated	`NCT02376933` - Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer	N/A